Kura Oncology Net Debt 2011-2026 | KURA

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities^[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Kura Oncology

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-216 M	-26.5 M	-40.3 M	-83.8 M	-319 M	-18.6 M	154 M	-4.34 M	55.7 M	-15.4 M	1.4 M	213 K	165 K	116 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
154 M	-319 M	-36.6 M

References

Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer	Net Debt	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	163 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	-1.06 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	-402 M	-	-	$ 40.3 B	USA
Apellis Pharmaceuticals APLS	-311 M	$ 20.7	-1.24 %	$ 2.61 B	USA
Aptorum Group Limited APM	-2.77 M	$ 0.84	7.59 %	$ 4.58 M	China
Biophytis SA BPTS	-4.01 M	-	-13.47 %	$ 169 M	France
Axsome Therapeutics AXSM	-205 M	$ 166.38	1.52 %	$ 8.28 B	USA
AbCellera Biologics ABCL	14.7 M	$ 3.82	5.82 %	$ 1.14 B	Canada
EyeGate Pharmaceuticals, Inc. EYEG	-824 K	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-6.17 M	-	-18.52 %	$ 27.3 M	Britain
Burford Capital Limited BUR	-135 M	$ 8.73	3.44 %	$ 1.37 B	Britain
Capricor Therapeutics CAPR	-12.5 M	$ 26.86	-3.83 %	$ 719 M	USA
Codexis CDXS	12.5 M	$ 1.02	0.99 %	$ 74.9 M	USA
Adverum Biotechnologies ADVM	31.1 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	246 M	-	-	-	Russia
Cellectis S.A. CLLS	-206 M	$ 3.8	-2.06 %	$ 116 M	France
ARCA biopharma ABIO	-60.6 M	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	-2.08 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	-63.9 M	-	-	$ 2.17 B	USA
CNS Pharmaceuticals CNSP	-13.6 M	$ 3.13	-0.95 %	$ 1.2 M	USA
Acorda Therapeutics ACOR	114 M	-	-24.86 %	$ 820 K	USA
Collegium Pharmaceutical COLL	-226 M	$ 41.6	-0.17 %	$ 1.32 B	USA
Corcept Therapeutics Incorporated CORT	-114 M	$ 35.97	0.76 %	$ 3.74 B	USA
Catalyst Pharmaceuticals CPRX	-706 M	$ 23.88	3.47 %	$ 2.92 B	USA
Acasti Pharma ACST	-27.4 M	-	4.01 %	$ 150 M	Canada
Corbus Pharmaceuticals Holdings CRBP	263 K	$ 8.35	-2.57 %	$ 36.1 M	USA
Curis CRIS	-17 M	$ 1.08	-5.26 %	$ 6.81 M	USA
Crinetics Pharmaceuticals CRNX	-53 M	$ 40.68	-1.02 %	$ 3.83 B	USA
Corvus Pharmaceuticals CRVS	-10.6 M	$ 17.89	-2.03 %	$ 859 M	USA
Champions Oncology CSBR	-8.23 M	$ 6.07	2.71 %	$ 82.9 M	USA
Citius Pharmaceuticals CTXR	-2.99 M	$ 0.72	-2.3 %	$ 4.84 M	USA
CEL-SCI Corporation CVM	3.45 M	$ 3.83	-10.09 %	$ 244 M	USA
CureVac N.V. CVAC	-783 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	-65.1 M	-	5.93 %	$ 314 M	Canada
Daré Bioscience DARE	-14.4 M	$ 1.61	-5.29 %	$ 13.7 M	USA
DBV Technologies S.A. DBVT	-25.5 M	$ 23.25	10.77 %	$ 2.26 B	France
AgeX Therapeutics AGE	12.6 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-30.2 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-36 M	-	-	$ 26.5 M	USA
Precision BioSciences DTIL	-108 M	$ 4.33	3.1 %	$ 16.6 M	USA
AIkido Pharma AIKI	-1.04 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	-60.8 M	$ 3.34	0.3 %	$ 1.2 M	USA
Dyadic International DYAI	-6.38 M	$ 0.77	-1.68 %	$ 22.2 M	USA
Ayala Pharmaceuticals AYLA	-657 K	-	-	$ 7.46 M	Israel
Editas Medicine EDIT	-64.5 M	$ 2.15	-2.27 %	$ 177 M	USA
Edesa Biotech EDSA	-7.74 M	$ 2.28	3.64 %	$ 7.29 M	USA
Akero Therapeutics AKRO	-340 M	-	-	$ 3.67 B	USA
Agios Pharmaceuticals AGIO	-48.9 M	$ 29.2	-3.41 %	$ 1.69 B	USA
Advaxis ADXS	3.42 M	-	-9.65 %	$ 45.9 M	USA
Equillium EQ	-22.4 M	$ 1.92	5.49 %	$ 66.7 M	USA